Cogent Biosciences announced that its phase 3 trial for bezuclastinib in indolent systemic mastocytosis met the primary endpoint, positioning the drug for potential FDA approval. The compound targets a relatively common immune disorder characterized by allergic and systemic symptoms. Success in this pivotal trial could enable Cogent to challenge existing therapies and expand treatment options for mastocytosis patients.